

CITATION REPORT

List of articles citing

Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review

DOI: 10.1016/j.jaad.2020.04.024

Journal of the American Academy of Dermatology,
2020, 83, 563-578.

Source: <https://exaly.com/paper-pdf/77539638/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
57	COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020 , 49, 763-773	2.6	13
56	Update on antimalarials and systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 572-582	5.3	6
55	Novel case of an adult with toxic shock syndrome following COVID-19 infection. <i>American Journal of Ophthalmology Case Reports</i> , 2020 , 20, 100843	1.3	2
54	A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?. <i>Clinical and Molecular Allergy</i> , 2020 , 18, 19	3.7	12
53	Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1617-1624	4.1	3
52	Cutaneous Manifestations in Confirmed COVID-19 Patients: A Systematic Review. <i>Biology</i> , 2020 , 9,	4.9	26
51	Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations. <i>Archives of Dermatological Research</i> , 2021 , 313, 611-622	3.3	9
50	Dermatologic manifestations of hydroxychloroquine therapy: A closer look at the nails. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, e291-e292	4.5	1
49	A clinicopathological study of eight patients with COVID-19 pneumonia and a late-onset exanthema. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e460-e464	4.6	26
48	Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e457-e459	4.6	35
47	Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine. <i>Dermatologic Therapy</i> , 2020 , 33, e13565	2.2	12
46	Facts, not Fear: Safety of Hydroxychloroquine. <i>American Journal of the Medical Sciences</i> , 2020 , 360, 199-200		2
45	Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19. <i>Dermatologic Therapy</i> , 2020 , 33, e13834	2.2	6
44	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. <i>Advances in Rheumatology</i> , 2020 , 60, 32	3	24
43	Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review. <i>Dermatologic Therapy</i> , 2020 , 33, e13986	2.2	57
42	Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 2777-2779.e1	5.4	14
41	Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1527-1529	4.5	1

40	Cutaneous Manifestations of COVID-19: A Systematic Review. <i>Advances in Wound Care</i> , 2021 , 10, 51-80	4.8	44
39	Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1162, 122469	3.2	1
38	A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. <i>Dermatologic Therapy</i> , 2021 , 34, e14662	2.2	15
37	Longitudinal melanonychia and skin hyperpigmentation associated with hydroxychloroquine therapy. <i>JAAD Case Reports</i> , 2021 , 7, 23-25	1.4	1
36	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. <i>Clinical Toxicology</i> , 2021 , 59, 12-23	2.9	24
35	Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. <i>Topics in Current Chemistry</i> , 2021 , 379, 4	7.2	8
34	Acute Generalized Exanthematous Pustulosis (AGEP) in 12 Patients Treated for SARS-CoV-2 Positive Pneumonia. <i>American Journal of Dermatopathology</i> , 2021 , 43, 342-348	0.9	6
33	Hydroxychloroquine-induced acute generalized exanthematous pustulosis: a series of seven patients and review of the literature. <i>International Journal of Dermatology</i> , 2021 , 60, 742-748	1.7	2
32	Adsorption and removal of hydroxychloroquine from aqueous media using Algerian kaolin: Full factorial optimisation, kinetic, thermodynamic, and equilibrium studies. <i>International Journal of Environmental Analytical Chemistry</i> , 1-22	1.8	8
31	Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19. <i>Dermatologic Therapy</i> , 2021 , 34, e14806	2.2	3
30	Cutaneous Vasculopathy in a COVID-19 Critically Ill Patient: A Histologic, Immunohistochemical, and Electron Microscopy Study. <i>Case Reports in Critical Care</i> , 2021 , 2021, 6644853	1	1
29	A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interaction. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021 , 1-14	3.6	0
28	Computational and synthetic biology approaches for the biosynthesis of antiviral and anticancer terpenoids from <i>Bacillus subtilis</i> . <i>Medicinal Chemistry</i> , 2021 ,	1.8	
27	Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge. <i>Journal of Medical Virology</i> , 2021 , 93, 5756-5767	19.7	14
26	Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practice Outcomes among Health-Care Workers.		
25	Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2021 , 2021, 5942366	2.6	2
24	Blue Facial Discoloration during Advanced Cancer and a Pandemic. <i>Journal of Pain and Symptom Management</i> , 2021 , 62, e328-e332	4.8	
23	Cutaneous drug eruptions associated with COVID-19 therapy. <i>JAAD International</i> , 2020 , 1, 73-76	0.9	4

22	COVID-19 and the Eye: A Comprehensive Review of the Literature. <i>International Ophthalmology Clinics</i> , 2021 , 61, 1-14	1.7	4
21	Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. <i>Indian Journal of Medical Research</i> , 2021 , 153, 219-226	2.9	1
20	Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus. <i>Drugs in Context</i> , 2020 , 9,	5.2	1
19	Response to: "Dermatologic manifestations of hydroxychloroquine therapy: A closer look at the nails". <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, e293	4.5	
18	Hydroxychloroquine Induced Melanosis. <i>Reumatología Clínica</i> , 2021 ,	0.9	
17	SKIN DISEASES CAUSED BY THE SARS-COV-2 VIRUS AND THEIR INCREASE DURING THE USE OF PERSONAL PROTECTIVE EQUIPMENT. <i>Emergency Medical Service</i> , 2021 , 8, 265-270	0	
16	Acute and subacute oral toxicity of artemisinin-hydroxychloroquine sulfate tablets in rats.. <i>Regulatory Toxicology and Pharmacology</i> , 2022 , 129, 105114	3.4	2
15	Introduction on therapeutic opportunities for autoimmunity. 2022 , 1-11		
14	Skin manifestations in patients with coronavirus disease 2019.. <i>Current Opinion in Infectious Diseases</i> , 2022 , 35,	5.4	0
13	A temporal cluster of cutaneous drug eruptions developing after initiation of hydroxychloroquine.. <i>Scandinavian Journal of Rheumatology</i> , 2022 , 1-3	1.9	0
12	Disorders of Hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders.. <i>Journal of the American Academy of Dermatology</i> , 2022 ,	4.5	0
11	Oral pigmentation as an adverse effect of chloroquine and hydroxychloroquine use: A scoping review.. <i>Medicine (United States)</i> , 2022 , 101,	1.8	0
10	Drug eruption: A mimicker of Coronavirus disease-2019 rash. <i>Turkderm</i> , 2022 , 56, 34-38	2	0
9	AGEP sine pustulosis induced by hydroxychloroquine used for COVID-19 infection.. <i>Dermatologic Therapy</i> , 2021 , e15263	2.2	
8	Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 740707	5.6	0
7	Rash morphology as a predictor of COVID-19 severity: A systematic review of the cutaneous manifestations of COVID-19. <i>Skin Health and Disease</i> ,		0
6	Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions.. <i>Expert Opinion on Drug Safety</i> , 2022 , 1-9	4.1	0
5	Hydroxychloroquine induced melanosis. <i>Reumatología Clínica (English Edition)</i> , 2022 , 18, 377-378	0.1	

- 4 Why lupus patients discontinue antimalarials in real life: A 50 years-experience from a reference centre. *Lupus*, 096120332211156 2.6 ○
- 3 Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic. ○
- 2 Synthesis of Reduced Graphene Oxide by Ethyl Acetate and Its Utilization in Determining Hydroxychloroquine in Wastewater and Pharmaceutical Samples. **2022**, 7, ○
- 1 Papulovesicular skin rash as early sign of COVID-19: a case report. **2022**, 10, 172-177 ○